INSMED Inc 8-K

What Happened

• Insmed Incorporated announced its financial results for the three months and fiscal year ended December 31, 2025 in a press release issued February 19, 2026 (furnished with the Form 8‑K).
• Separately, on February 17, 2026 director David W.J. McGirr notified the board he will not stand for re‑election as a Class II director at the Company’s 2026 Annual Meeting; he will continue to serve on the board and as chair of the Audit Committee until the Annual Meeting. The company says his decision was not due to any disagreement with Insmed on operations, policies or practices.

Key Details

• Filing dated February 19, 2026 reporting results for the three months and fiscal year ended December 31, 2025 (Item 2.02).
• Director notice given February 17, 2026; Mr. McGirr is a Class II director and current Audit Committee chair (Item 5.02).
• Press release and investor presentation were furnished as exhibits with the 8‑K (Exhibits 99.1 and 99.2).
• Company stated Mr. McGirr will remain in his roles until the 2026 Annual Meeting and that there was no disagreement with management.

Why It Matters

• The press release and presentation contain the financial details (earnings, revenue, cash flow and any guidance) that can affect the stock; investors should review those exhibits to assess performance and outlook for FY 2025.
• The announced departure of the Audit Committee chair is a governance development to monitor — however, because Mr. McGirr will remain in place until the Annual Meeting and the company notes no disagreement, immediate governance disruption appears limited.
• Watch for upcoming proxy/board notices about who will succeed him and for any follow‑up disclosures that provide the specific Q4/FY financial metrics.